ישראל - עברית - Ministry of Health

comex ltd - water for injections 100 % - solvent for parenteral use - for use as a sterile solvent for the preparation of medicine intended for parenteral administration where water is a component of the preparation and for reconstituting or diluting medicines for parenteral administration immediatly after use.

ישראל - עברית - Ministry of Health

dr.samuelov importing & marketing ltd, israel - agni casti fructus dry extract: 20% (7-11:1) extraction solvent ethanol 70% v/v) - טבליות מצופות פילם - agni casti fructus dry extract: 20% (7-11:1) extraction solvent ethanol 70% v/v) 4 mg - agni casti fructus

ישראל - עברית - Ministry of Health

dr.samuelov importing & marketing ltd - dry extract from cimicifuga racemosa (l.) nutt, rhizoma (black cohosh) (5-10:1) extraction solvent: ethanol 58% (v/v) - טבליות מצופות פילם - dry extract from cimicifuga racemosa (l.) nutt, rhizoma (black cohosh) (5-10:1) extraction solvent: ethanol 58% (v/v) 2.8 mg - cimicifugae rhizoma

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - epoprostenol as sodium 1.5 mg - powder and solvent for solution for infusion - epoprostenol - epoprostenol teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - epoprostenol as sodium 0.5 mg - powder and solvent for solution for infusion - epoprostenol - epoprostenol teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - ceftriaxone as sodium 1000 mg/vial - powder and solvent for solution for injection - ceftriaxone - long-acting, broad spectrum cephalosporin, for the treatment of infections caused by susceptible organisms.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - powder and solvent for solution for injection - meningococcal vaccines group y 5 mcg / 0.5 ml; meningococcal vaccines group w 5 mcg / 0.5 ml; meningococcal vaccines group c 5 mcg / 0.5 ml; meningococcal vaccines group a 10 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.

ישראל - עברית - Ministry of Health

abic marketing ltd - docetaxel 27.73 mg / 1 ml - concentrate and solvent for solution for infusion - docetaxel - breast cancerdocetaxel teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.docetaxel teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.docetaxel teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have inclu

ישראל - עברית - Ministry of Health

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

ישראל - עברית - Ministry of Health

הדים מכונים אודיולוגים בע"מ - כלל האוכלוסיה